Study Suggests Drug-and-Vibration Approach May Help Move Proteins Out of the Brain, but It Is Not a Dementia Treatment

Researchers at the University of Oulu in Finland reported on Nov. 3 that an experimental combination of a blood-vessel-dilating drug and targeted whole-body vibration may increase the movement of brain-derived proteins into the bloodstream. The study, published in Nature Communications, involved 29 healthy adults. Participants received sublingual nitroglycerin and a vibration intervention designed to engage the Piezo1 pathway, while researchers used brain imaging and blood biomarkers to track physiological changes. The findings offer a new clue about brain-fluid transport, but they do not show that the method prevents or treats Alzheimer’s disease. They also do not provide a basis for people to take nitroglycerin or use vibration devices on their own.

How the experiment worked

The researchers combined a pharmacological intervention with mechanical stimulation. Sublingual nitroglycerin was used to cause blood-vessel dilation through nitric-oxide signaling. Participants also received carefully modulated whole-body vibration intended to stimulate Piezo1 mechanosensitive channels in vascular tissue. The trial used a randomized crossover design, with participants undergoing different interventions on separate days. The team combined multimodal magnetic resonance imaging, measurements of brain-fluid dynamics and blood-based biomarkers to look for signs that soluble proteins originating in the brain were moving into circulation.

What the researchers observed

After the combined intervention, the researchers found increases in blood levels of brain-derived proteins including amyloid-beta Aβ40, Aβ42 and GFAP. Imaging measurements also showed changes in brain-fluid dynamics and cerebrospinal-fluid-related spaces. The authors said the findings were consistent with a transient redistribution of soluble brain-derived proteins toward the venous circulation. Blood pressure fell during the combined protocol, and the size of the pressure reduction correlated with changes in some protein markers. The study did not follow participants to determine whether they later experienced changes in memory or cognitive function, and it did not demonstrate a clinical benefit.

Biomarker changes are not proof of treatment

The study involved 29 healthy volunteers, not patients diagnosed with Alzheimer’s disease or another form of dementia. It examined short-term physiological changes and blood markers rather than long-term cognition, disease incidence or progression. The authors also noted that the precise pathways responsible for brain-solute clearance remain incompletely understood. Nitroglycerin can cause headache, nausea and a drop in blood pressure. In the study, several participants reported temporary symptoms and one session was stopped after vomiting. The intervention was performed under controlled experimental conditions and should not be interpreted as a do-it-yourself treatment.

Larger clinical studies are still needed

The findings provide a hypothesis for further research into the relationship between brain-fluid circulation and neurodegenerative disease. Future studies will need larger and more diverse groups to test whether the effect lasts, whether it applies to older or higher-risk populations and whether the approach is safe over time. Researchers will also need to compare the drug alone, vibration alone and the combined protocol, while measuring outcomes that matter to patients, such as cognition and daily functioning. For now, the careful conclusion is that an experimental approach may influence the movement of brain-derived proteins. It has not been shown to prevent dementia.